Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
1 A; `( Q, ^ I- e( M" m' ?1 X& D0 f' l; i7 N
- X8 b$ J6 I* tSub-category:
7 _, ~- [1 q( q( _ O$ zMolecular Targets ( _& d) w3 e/ E3 L( V
2 b& k/ [ u1 a1 ~3 [6 ~% F# U$ n- ^; Q& h1 ]
Category:2 z0 B& G7 J9 H. e0 H
Tumor Biology
2 j/ U( s+ A) a( X8 O$ B" }3 X8 E( ?8 r, u
/ N; j, @; L6 \1 x$ N
Meeting:
, m, K) A) g8 x ?% |2011 ASCO Annual Meeting 5 @- i3 [$ {6 n, {4 r, o; r- H
0 X8 X0 h: }! B1 E0 ?
6 o5 ]6 A4 m0 |( S" L6 K: _$ }6 jSession Type and Session Title:) b9 \9 t0 K; k! |2 U) y
Poster Discussion Session, Tumor Biology 5 l* ~' L- p/ M. ^$ x& o( u1 H4 |
% N: v1 m& q: {! [2 y/ @
% G- L3 C" V4 N3 fAbstract No:, @' }9 c" ~, B: {6 d* c% x3 d) V
10517 7 w" o/ u# \! k# c' w- X
s5 }3 N5 q$ ]7 A7 N; ^5 N
5 Q* B; b3 @7 L5 T' s8 u: @/ iCitation:5 P% z# g- C" d8 F+ j1 t
J Clin Oncol 29: 2011 (suppl; abstr 10517)
) M- X! r' g4 [. S$ }. K# U
4 T. p% F4 x0 J- P4 y% o0 S. j" m1 F6 M3 {, Y
Author(s):
+ F0 S! a, F4 b7 [9 U( [2 @- D7 lJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 D, @" E3 G. M( m* Z6 q, v5 P4 w- e& E1 ^( Z+ g+ {
/ T1 [; T0 G& I0 ]4 o( h" M6 ?! `
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.- B) l6 T# W$ R! S
& n& P5 w- L; W8 yAbstract Disclosures+ u! m) u4 A7 `" h' [
3 K2 A- ^6 t7 E6 P2 J' q( wAbstract:/ g6 s$ \+ d$ f
. W0 Z+ ]- |4 n2 T# J1 k; \/ k4 [1 g: m/ T7 a& E3 H! m
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." _( Q* x! q" I$ \( q T1 N4 b
% h w+ O3 }: ~3 A: t+ e* i
) L% W* R7 P/ n8 j9 w |